Largely, no, and there is no test that reliably fixes this.

Combined pills suppress estrogen, FSH, and LH so thoroughly that these hormones stay suppressed even when measured during the placebo week, so blood tests cannot be used to judge menopausal status. The pill also controls bleeding patterns and can suppress symptoms, and it lowers markers like AMH and antral follicle count that are sometimes marketed as ovarian-reserve or menopause-timing tests, so none of the usual signals are reliable while you are on it. The guideline itself states plainly that contraception can mask the signs of menopause without changing when it actually happens, and offers no way around that trade-off other than stopping. There is also a second, different sense in which the pill can "mask" the transition: the estrogen and progestin in a combined pill are synthetic compounds, not the same molecules as your own estradiol and progesterone, and they work partly by suppressing your body's own hormone production. Ethinylestradiol, the estrogen in most pills, binds estrogen receptors differently than your own estradiol and is metabolized very differently. The synthetic progestin in a pill is not the same molecule as your own progesterone either, and different progestins vary widely in how they affect the calming, GABA-related pathway your own progesterone feeds through its breakdown product, allopregnanolone. In plain terms: taking a hormone is not the same as taking your own hormone, so having hormones from the pill does not automatically mean nothing hormonal could still be contributing to how you feel.

What to know about this answer

One clinician in the source material describes a partial workaround, testing FSH at the very tail end of the pill-free days, but this is directly contradicted by the guideline's own wording on the same point, so it is presented as a field practice the guideline explicitly does not support.

What the research shows, and which source each finding rests on

Women using combined hormonal contraception have very suppressed levels of estradiol, FSH, and LH even when measured during the hormone-free interval, so these cannot be used to judge menopausal status.

A[1]

A national guideline body advises that FSH blood tests should not be used to identify menopause in people using combined estrogen and progestogen contraception or high-dose progestogen, because these methods affect the test result without improving management.

A[2]

AMH, antral follicle count, and ovarian volume are all measurably lower in hormonal contraception users versus non-users after adjusting for age, meaning these ovarian-reserve markers are not reliable for staging the transition in someone using hormonal contraception.

D[3]

Contraception does not affect the onset or duration of menopausal symptoms, but it may mask the signs and symptoms of menopause; this is a formal guideline recommendation, not a settled way of resolving the trade-off.

A[1]

Ethinylestradiol, the synthetic estrogen in most combined pills, is a structurally different molecule from the body's own estradiol: it binds estrogen receptors with different affinity, resists the liver's usual breakdown so more of it stays active, and drives a much larger rise in liver-made proteins such as clotting factors than natural estradiol does.

E[5]

The synthetic progestin in a pill is a different molecule from the body's own progesterone, and progestins vary widely in how they affect the calming, GABA-related neurosteroid pathway that natural progesterone feeds through its breakdown product allopregnanolone, mainly depending on how androgenic the specific progestin is.

E[6]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

no reliable signal survives, stop to find out

the guideline and most clinicians in the source material

The guideline states hormone levels are suppressed even when drawn during the hormone-free interval specifically to close this loophole; the only way to get an interpretable reading is to stop the method for a period of time.

A[1]

a partial signal can sometimes be caught at the tail end of the pill-free days

one clinician in the source material

This clinician has suggested that an FSH level can sometimes still rise despite the pill, and that testing at the very end of the placebo days may occasionally catch that rise.

E[4]

What would settle it: A study measuring FSH serially across the hormone-free interval in perimenopausal pill users, compared against a later off-treatment reference standard, would settle this. It would be straightforward to run and has not been done.

What is really going on here

  1. This is described in the source material as a genuine information blind spot with no clinical solution, not a gap in a woman's knowledge or her clinician's competence; a woman on a combined pill for many years has no reliable way to know what has already happened in her transition.
  2. Bleeding pattern, the usual diagnostic signal for perimenopause, is also controlled by the pill and therefore cannot be used either.
  3. Is the hormone in a birth control pill actually the same molecule as the hormone your own body makes, or a synthetic compound built to act like it?
  4. If it is a different molecule, what does the research actually show about where its effects match your own hormones and where they diverge, especially for mood, sleep, and anxiety?

Questions for your doctor

  1. Is there any reliable way to estimate where I am in the transition while staying on my current method?
  2. If I wanted to find out, what would stopping involve, and for how long?
  3. Would knowing my stage actually change how we manage my care right now?
  4. Are there symptoms I should watch for even while my hormones are suppressed by the pill?

Questions with no answer yet

Would testing FSH at the very tail end of the pill-free days actually catch a genuine rise, or is this contradicted by the guideline's finding that hormone levels stay suppressed even during the hormone-free interval?

Studied and negative

What is known: The guideline states plainly that women using combined hormonal contraception have very suppressed levels of estradiol, FSH, and LH even when measured during the hormone-free interval, specifically closing this loophole; the suggestion that testing at the tail end of pill-free days can sometimes catch a rise is a field practice the guideline explicitly does not support.

What would test it: A study measuring FSH serially across the hormone-free interval in perimenopausal pill users, compared against a later off-treatment reference standard; this would be straightforward to run and has not been done.

Is there any biomarker, beyond FSH, estradiol, LH, AMH, or antral follicle count, that could reliably indicate a woman's stage in the transition while she remains on combined hormonal contraception?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: All the standard markers currently used to stage the transition are each separately shown to be suppressed or unreliable while a woman is on combined hormonal contraception; no alternative marker is identified in the source material as having been tested for this purpose.

What would test it: Research identifying and validating a transition-stage marker that is not suppressed by combined hormonal contraception, if one exists.

If a woman on the pill still has mood, sleep, or anxiety symptoms, could that be explained by her synthetic hormones not fully replicating her own hormones' effects, rather than by something unrelated to hormones at all?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: It is separately documented that ethinylestradiol behaves differently from a woman's own estradiol, and that synthetic progestins vary in how they affect the same calming neurosteroid pathway natural progesterone feeds. No study has directly tested whether these documented molecular differences explain residual mood, sleep, or anxiety symptoms in women using combined contraception during the perimenopausal years specifically.

What would test it: A study comparing residual symptom burden in perimenopausal pill users across progestins with different androgenicity, or comparing symptom burden on pills built around natural estradiol/estetrol versus ethinylestradiol, with mood, sleep, and anxiety as prespecified outcomes.

Sources

  1. 1.FSRH. Contraception for Women Aged Over 40 Years. Guideline, August 2017 (amended September 2019, further amended July 2023).Systematic review or guideline
  2. 2.NICE NG23. Menopause: identification and management (2024 update).Systematic review or guideline
  3. 3.Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.Bentzen JG, Forman JL, Pinborg A, Lidegaard O, Larsen EC, Friis-Hansen L, Johannsen TH, Nyboe Andersen A. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online 2012;25(6):612-9. · Comparative or small study
  4. 4.Felice Gersh, MD. Birth control for perimenopause? Pros and Cons and how to decide (video transcript).Review, opinion or mechanism
  5. 5.Comparison of estrogenic components used for hormonal contraception.Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Comparison of estrogenic components used for hormonal contraception. Contraception 2023;130:110310. · Review, opinion or mechanism
  6. 6.Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice.Fruzzetti F, Fidecicchi T. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clin Drug Investig 2020;40(12):1097-1106. · Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides